Title
Category
Credits
Event date
Cost
Smoking Cessation for Patients with Cancer: State of the Evidence
  • Smoking Cessation
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
$0.00
Smoking is not only linked to the development of tobacco-related cancers, but also to the prognosis upon diagnosis and risk of death during treatment. Clinicians must understand the complexity of smoking cessation interventions in this patient population to mitigate smoking-associated risks and improve patient outcomes.
Expansion of Recommendations for Hereditary Cancers
  • Genetic/Familial High-Risk Assessment
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
$0.00
The prevalence of genetic predisposition to cancer is greater than initially appreciated. Due to the increase in multigene testing and the evidence-base surrounding genes and hereditary syndromes associated with cancer, the recommendations in the NCCN Guidelines for Genetic/Familial High-Risk Assessment have expanded and adapted accordingly.
Optimizing Patient Outcomes - Targeted Therapies for Thyroid Carcinoma
  • Thyroid Cancer
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
05/21/2025
$0.00
Thyroid carcinoma is a rare disease; however, it is the seventh most common cancer diagnosed in those assigned female at birth. Greater attention to rare diseases is needed to improve treatment options in general, and specifically for anaplastic thyroid carcinoma.  Pharmacists can play a role in appropriate treatment selection, monitoring, and modification.
NCCN Tumor Boards: New Approaches to the Management of Resectable Non-Small Cell Lung Cancer
  • Lung Cancers
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
05/22/2025
$0.00
In recent years, several new systemic therapy regimens were approved by the FDA as additional neoadjuvant or adjuvant treatment options for eligible patients with resectable NSCLC and included in the NCCN Guidelines for NSCLC. Clinicians need to be aware of the updated treatment recommendations to ensure optimal outcomes for patients with early-stage NSCLC.
NCCN Tumor Boards: Treatment Options and Navigating Sequencing of Therapies in Relapsed/Refractory Multiple Myeloma
  • Multiple Myeloma
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
05/23/2025
$0.00
With the introduction of many new therapies, the management of multiple myeloma is rapidly changing. A uniform treatment approach cannot be applied to all patients.
Expert Perspectives on Updates and Advances in Individualizing CLL/SLL Therapy Across the Disease Course
  • Chronic Lymphocytic Leukemia
  • 1.50 AAPA Category 1 CME credit
  • 1.50 ABIM Medical Knowledge
  • 1.50 ACPE contact hours
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 ANCC contact hours
  • 1.50 Participation
05/30/2025
$0.00
Join us for this dynamic, case-based, live symposium in collaboration with the NCCN to hear from an expert panel on current recommendations and emerging strategies for treating patients with CLL.
Optimizing Patient Outcomes - Understanding the Mismatch Repair Deficient (dMMR)/Microsatellite-High (MSI-H) Treatment Options in Upper Gastrointestinal Cancers
  • Gastric/Esophageal Cancer
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
07/23/2025
$0.00
The standards of care for the treatment of MSI-H/dMMR esophageal, esophagogastric junction, and gastric cancers are constantly evolving. There is a need to review the current landscape of treatment regimens and understand how to incorporate the new standards of care to treat this patient population effectively.
Optimizing Patient Outcomes - New Primary Therapy Options for Stage III-IV Hodgkin Lymphoma
  • Hodgkin Lymphoma
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
08/14/2025
$0.00
With the addition of two new regimens for the treatment of stage III-IV advanced Hodgkin lymphoma, it is important for the interprofessional oncology care team to be aware of new therapy recommendations in order to provide support by monitoring for drug interactions and adverse drug reactions, understanding the toxicities associated with these agents, and providing patient education.

Pages